Clinical trials of Lymfactin®, an adenovirus-based gene therapy and pro-lymphangiogenic growth factor vector that induces vascular endothelial growth factor C (VEGF-C) expression, have not shown any significant improvement in primary outcomes of lymphoedema severity compared with vLNT alone, although there was improvement in some secondary outcomes and the treatment was well tolerated134. The gene discussed is VEGFC; the disease is lymphedema.